INS and metabolic syndrome: In obesity, dyslipidemia, and mouse model studies [20], the level of GLP-1 in serum has also been shown to be increased, affecting IL-6 secretion, IL-6 production, and hepatic gluconeogenesis, which results in moderate tolerance to insulin and blood glucose lowering [21], thereby promoting insulin secretion, promoting pancreatic β cell proliferation, controlling muscle cell glycogen synthesis, controlling fiber amounts, and providing satiety [22].